Zhaohui Su, VP, Strategic Consulting at Veristat, shared a post on LinkedIn:
“From five weeks to five days. This is the gap between database lock and submission-ready tables, listings, and figures that Veristat‘s new InStat platform will close.
InStat is a zero-code, fully automated biostatistics solution featuring validated statistical engines and biostatistician review in the loop. It offers speed without regulatory risk and is already supporting Clene Nanomedicine’s planned 2026 NDA.
For companies racing toward regulatory submissions, there is an opportunity to explore how this platform might help your studies.’
Other articles featuring Zhaohui Su on OncoDaily.